You searched for "disease"
Long-term oncologic outcomes of salvage cryoablation for rrPC
Of patients undergoing radiotherapy (RT) for prostate cancer (PC), at least 15-20% will experience recurrence. Although salvage prostatectomy achieves durable oncological outcomes at 10 years, it is associated with significantly high morbidity. Thus, the majority of men with radio-recurrent prostate...
Intravesical cytosine arabinoside + Mitomycin C for bladder cancer – is it beneficial?
Mitomycin C (MMC) is often used as an intravesical therapy for low / intermediate risk non-muscle invasive bladder cancer. This randomised controlled trial (RCT) was designed to assess the safety and efficacy of MMC + cytosine arabinoside (Ara-C). Ara-C was...
AML – a rare variant
With the increasing number of CT and ultrasound scans performed in hospital practice more and more incidental angiomyolipomas (AML) are being picked up, some of which are asymptomatic and may not bother patients at all. This study comes from the...The Prostate Cancer Foundation awards more than $6 million to promising young investigators to advance prostate cancer research
The Prostate Cancer Foundation (PCF) announced that its 2024 Young Investigator Award programme has awarded a total of $6.3 million in funding to 30 promising next-generation researchers conducting innovative prostate cancer research. The PCF programme, now in its 27th year,...An update on lower pole stone management for 2015
Introduction Urolithiasis is an increasing healthcare problem, with an estimated lifetime prevalence of up to 15% [1]. The number of interventions undertaken for stone disease has increased dramatically over recent years, particularly with respect to ureteroscopy and percutaneous nephrolithotomy (PCNL)...Bladder cancer: where are we with intravesical therapies?
In the United Kingdom, almost 10,500 new cases of bladder cancer were identified in 2013, with over 5000 deaths in 2012 [1]. Seventy percent of new cases will be non-muscle invasive bladder cancer (NMIBC) at diagnosis and therefore will be...Keep patients at the heart of treatment decision
Rebecca Porta, Chief Executive of The Urology Foundation, and Chris Whitehouse, Chair of the Urology Trade Association, mark Urology Awareness Month. Rebecca Porta. Chris Whitehouse. Keep patients at the heart of treatment decision This September marked Urology Awareness Month (UAM),...The Malcolm Coptcoat Travelling Fellowship Award
The Urology Foundation and The Malcolm Coptcoat Trust are pleased to announce the creation of The Malcolm Coptcoat Travelling Fellowship. The annual Fellowship will support travel to international centres of excellence for a period of four to six weeks to...Clear cell urothelial carcinoma: a highly aggressive morphological variant in the bladder and upper urinary tract
Clear cell urothelial carcinoma (CCUC) is a rare morphological variant of transitional cell carcinoma (TCC). It can occur anywhere along the urothelial tract and is characterised histologically by high grade carcinoma with an abundance of clear, glycogen-rich cytoplasm [1]. Alternative...The impact of menopause on bladder symptoms
The menopause is a natural process of ageing when the ovaries completely stop producing reproductive hormones (oestrogen and other sex steroids), and there are no monthly periods for 12 consecutive months. It normally occurs between the ages of 45-55 years...
MRI targeted transperineal prostate biopsy: a local anaesthetic approach
Transperineal template biopsy remains the gold standard investigation in diagnosis of prostate cancer. Data from the PROMIS study demonstrated the low sensitivity of transrectal ultrasound (TRUS) biopsy as a diagnostic tool, and highlighted the need for a better diagnostic pathway....
